Premium
P4‐556: DEPRESSION DIAGNOSIS IS PREDICTED BY TAU IMAGING BIOMARKER AMONG COGNITIVELY NORMAL ADULTS
Author(s) -
Babulal Ganesh M.
Publication year - 2019
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2019.08.103
Subject(s) - depression (economics) , medicine , dementia , biomarker , positron emission tomography , antidepressant , psychology , logistic regression , neuroimaging , oncology , clinical psychology , disease , psychiatry , nuclear medicine , hippocampus , economics , macroeconomics , biochemistry , chemistry
Background: Depression is both a risk factor and consequence of Alzheimer disease (AD). Biomarker studies using cerebrospinal fluid and amyloid Positron Emission Tomography (PET) have found higher levels of AD biomarkers are associated with the development of depressive symptoms over time. This study examines whether tau and amyloid imaging predict a depression diagnosis among cognitively normal adults and whether antidepressant use modifies this relationship. Methods: Cognitive normal participants (Clinical Dementia Rating1⁄4 0) were enrolled from the Knight Alzheimer’s Disease Research Center at Washington University. Logistic regression models evaluated whether, in vivo tau PET (Flortaucipir), predicted depression diagnosis, after adjusting for covariates including age, sex, education, and race. Similarly, a second model tested the statistical interaction between tau PETand antidepressant use in predicting depression, while adjusting for the same covariates. A second set of models were conducted substituting tau PET with amyloid PET imaging (Florbetapir). Secondary analyses examined group differences on depressive symptoms, neuropsychiatric symptoms, and cognitive function. Results: Data were available from 301 cognitively normal participants (46.2 to 91.3 years old and mean of 69.5 (SD1⁄48.0)). Participants with higher tau PET were twice more likely to be depressed (OR:2.17; 95% CI: 1.0, 4.6). The interaction between tau and antidepressant use was also significant (p1⁄4.027) suggesting those with higher tau and taking antidepressants had a great risk of depression. Relatedly, amyloid was not statistically significant (p>.05) in predicting depression in any model. Finally, there were no group differences between participants with higher vs. lower levels of tau or amyloid on depressive symptoms, neuropsychiatric symptoms, and cognitive function.Conclusions: Our results demonstrate that tau, not amyloid PET predicts depression diagnosis, however, there was no relationship with depressive symptoms. Additionally, antidepressant use interacts with tau to increase the risk of depression among cognitively normal adults.